



	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Err
1	IS&R	L1	5	((("4795741") or	USPAT	2003/04/08			0
2	BRS	L2	95472	encapsul\$	USPAT	2003/04/08			0
3	BRS	L3	7802	embol\$	USPAT	2003/04/08			0
4	BRS	L4	4	1 and 3	USPAT	2003/04/08			0
5	BRS	L6	10981	vesicle\$1	USPAT	2003/04/08			0
6	BRS	L7	1	4 and 6	USPAT	2003/04/08			0
7	BRS	L5	2	4 and 2	USPAT	2003/04/08			0
8	BRS	L8	614	embol\$.ab,ti.clm.	USPAT	2003/04/08			0
9	BRS	L9	495572	particle\$ or	USPAT	2003/04/08			0
10	BRS	L10	228	8 and 9	USPAT	2003/04/08			0
11	BRS	L11	11469	contrast near5 (agent\$1 or	USPAT	2003/04/08			0
12	BRS	L12	7977	imaging near5 (agent\$1 or	USPAT	2003/04/08			0
13	BRS	L13	2814	(contrast or imaging) same	USPAT	2003/04/08			0
14	BRS	L14	17095	11 or 12	USPAT	2003/04/08			0
15	BRS	L15	19	10 and 13	USPAT	2003/04/08			0
16	BRS	L16	18	15 not 1	USPAT	2003/04/08			0
17	IS&R	L17	1	("6139819").PN.	USPAT	2003/04/08			0
18	BRS	L18	1	17 and 3	USPAT	2003/04/08			0

EAST - [default.wsp:1]

File View Edit Tools Window Help

L3: (7802)

L4: (4) 1 a

L6: (10981)

L7: (1) 4 a

L5: (2) 4 a

L8: (614) e

L9: (495572)

L10: (228)

L11: (11469)

L12: (7977)

L13: (2814)

L14: (17095)

L15: (19) 1

Failed

the proper form for in vivo use including a particle size of about 10 .mu.m or less. Other contrast agents suitable for use herein include gold and platinum.

Detailed Description Text - DETX (12):
The term "encapsulation " as used relative to the contrast agent being encapsulated in the precipitate is not meant to infer any physical entrapment of the contrast agent within the precipitate much as a capsule encapsulates a medicament. Rather, this term is used to mean that the contrast agent and copolymer form an integral coherent precipitate which does not separate into a copolymer component and a contrast agent component.

Detailed Description Text - DETX (15):

BRS form

IS&R form

Image

Text

HTML

	U	I	Document ID	Issue Date	P	Title	Current	Current X	Ret	Inv
16	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 5702361 A	19971230		Method for embolizing blood vessels	604/508	604/500		Evans, Sco
17	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 5695480 A	19971209	8	Embolizing compositions	604/264			Evans, Sco
18	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 5667767 A	19970916		Compositions for use in embolizing blood vessels	424/9.4 11	424/78.37		Greff, Ric al.
19	<input type="checkbox"/>	<input type="checkbox"/>	US 5580568 A	19961203	6	Cellulose diacetate compositions for use in	424/423	424/9.3; 424/9.322		Greff, Ric al.

His

Details

HTML

Ready

NUM

10/15/04 - 801,
4940
ur
M coag lumine
con range

FAST - [default.wsp:1]

File View Edit Tools Window Help

Drafts

Pending

Active

L1: (48) (me)

Failed

Saved

Favorites

Tagged (0)

UDC

Queue

Trash

The term "contrast agent" refers to a biocompatible (non-toxic) radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography. The contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodamide sodium, and meglumine. The term "water insoluble contrast agent" refers to contrast agents which are insoluble in water (i.e., has a water solubility of less than 0.01 milligrams per milliliter at 20.degree. C.) and include tantalum, tantalum oxide and barium sulfate, each of which is commercially available in the proper form for in vivo use and preferably having a particle size of 10 .mu.m or less. Other water insoluble contrast agents include gold, tungsten and platinum powders. Methods for preparing such water insoluble biocompatible contrast agents having

B&B form B&B form Image Text HTML

	U	1	Document ID	Issue Date	P	Title	Current	Current X	Ret	Inv
1	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6540789 B1	20030401	1	Method for treating morbid obesity	623/23.65	600/29; 607/40		Silverman, al.
2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6533717 B2	20030318		Method for treating fecal incontinence	600/29			Silverman, al.
3	<input type="checkbox"/>	<input type="checkbox"/>	US 6530878 B2	20030311	1	Method for vascular occlusive therapy	600/29			Silverman, al.
4	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6465686 B2	20021015		Halogenated 2-amino-5,6 heptenoic acid derivatives	562/439	560/125; 560/155;		Grapperhau L. et al.
5	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6465518 B2	20021015		Halogenated 2-amino-4, 5 heptenoic acid derivatives	514/565	562/560		Hansen, Jr et al.
6	<input type="checkbox"/>	<input type="checkbox"/>	US 6458337 B1	20021001		Diagnostic imaging contrast	424/9.2	424/1.11.		Apelli ni

Help Details HTML

Ready

NUM